Citation
Wang, Janice, et al. "Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): a Case Series." Journal of Thrombosis and Haemostasis : JTH, vol. 18, no. 7, 2020, pp. 1752-1755.
Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020;18(7):1752-1755.
Wang, J., Hajizadeh, N., Moore, E. E., McIntyre, R. C., Moore, P. K., Veress, L. A., Yaffe, M. B., Moore, H. B., & Barrett, C. D. (2020). Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. Journal of Thrombosis and Haemostasis : JTH, 18(7), 1752-1755. https://doi.org/10.1111/jth.14828
Wang J, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): a Case Series. J Thromb Haemost. 2020;18(7):1752-1755. PubMed PMID: 32267998.
TY - JOUR
T1 - Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
AU - Wang,Janice,
AU - Hajizadeh,Negin,
AU - Moore,Ernest E,
AU - McIntyre,Robert C,
AU - Moore,Peter K,
AU - Veress,Livia A,
AU - Yaffe,Michael B,
AU - Moore,Hunter B,
AU - Barrett,Christopher D,
Y1 - 2020/05/11/
PY - 2020/04/02/received
PY - 2020/04/04/accepted
PY - 2020/4/9/pubmed
PY - 2020/7/16/medline
PY - 2020/4/9/entrez
KW - COVID-19
KW - acute respiratory distress syndrome (ARDS)
KW - case report
KW - fibrinolysis
KW - tissue plasminogen activator (tPA)
SP - 1752
EP - 1755
JF - Journal of thrombosis and haemostasis : JTH
JO - J Thromb Haemost
VL - 18
IS - 7
N2 - A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.
SN - 1538-7836
UR - https://www.unboundmedicine.com/medline/citation/32267998/full_citation
L2 - https://doi.org/10.1111/jth.14828
DB - PRIME
DP - Unbound Medicine
ER -